Bio Path reported $-2970000 in Operating Profit for its third fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Baxter International BAX:US $ 250M 220M
Bio Path BPTH:US $ -2.97M 0.93M
Dicerna Pharmaceuticals DRNA:US $ -31.65M 8.75M
Karyopharm Therapeutics KPTI:US $ -37066000 10.04M
Seattle Genetics SGEN:US $ 164.99M 473.2M
Spectrum Pharmaceuticals SPPI:US $ -39.57M 3.08M